Is Citius Oncology Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: CTOR) stock is to Strong Buy CTOR stock.
Out of 1 analyst, 1 (100%) are recommending CTOR as a Strong Buy, 0 (0%) are recommending CTOR as a Buy, 0 (0%) are recommending CTOR as a Hold, 0 (0%) are recommending CTOR as a Sell, and 0 (0%) are recommending CTOR as a Strong Sell.
According to 1 Wall Street analyst that have issued a 1 year CTOR price target, the average CTOR price target is $3.00, with the highest CTOR stock price forecast at $3.00 and the lowest CTOR stock price forecast at $3.00.
The Wall Street analyst predicted that Citius Oncology's share price could reach $3.00 by Nov 27, 2025. The average Citius Oncology stock price prediction forecasts a potential upside of 277.83% from the current CTOR share price of $0.79.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.